HLA-Types, C-Peptide and Insulin Antibodies in Juvenile Diabetes*

J. Ludvigsson, J. Säfwenberg and L. G. Heding

Departments of Paediatrics, Linköping University, Linköping, and Blood Centre, University of Uppsala, Uppsala, Sweden, and Novo Research Institute, Copenhagen, Denmark

Summary. HLA-types were determined in 102 juvenile diabetics. HLA-B8 was found in 39 patients (RR 2.64; $p < 0.01$) and HLA-BW15 in 32 patients (RR 1.33; n.s.). HLA-B7 was found in 14 patients (RR 0.40; $p < 0.05$). There were no correlations between HLA-B8 or BW15 and family history of diabetes, occurrence of infection before onset of diabetes, ketonuria at onset or the age at onset of diabetes. Serum C-peptide, insulin binding capacity of IgG and total serum insulin, IRI, were determined in 94 patients who had had diabetes for more than two years and who were beyond the remission period. Measurable amounts of C-peptide were found in 33 patients (34.7%). There was no evidence of a relationship between any particular HLA-antigen and the B-cell function except for an increased incidence of detectable C-peptide in patients with HLA-B18 and a tendency to a decreased incidence of detectable C-peptide in patients with the combination HLA-B8, W15. Only four patients (4.3%) were lacking insulin antibodies. HLA-BW15 positive patients had higher levels of insulin antibodies than other groups, while HLA-B7 positive patients had lower levels. The results suggest that HLA-B7 and HLA-B18 might be associated with a different and perhaps milder form of juvenile diabetes.

Key words: Juvenile diabetes, HLA, C-peptide, insulin antibodies, total IRI.

The relative risk of getting insulin-dependent diabetes is increased for carriers of the HLA-antigens B8 and BW15 [1, 4, 6, 7, 8, 18, 24, 25, 26, 27, 29]. Among patients with insulin-dependent diabetes of short duration islet cell antibodies have been found more frequently in those with the HLA-DW3 antigen [23]. It has been suggested that, in patients with certain HLA-antigens, infections might provoke an immune response leading to B-cell destruction [14, 24]. The aim of this study was to examine the HLA-frequencies in children with juvenile diabetes and to relate the HLA-antigens to the age at onset of diabetes, the family history of diabetes, the occurrence of infections shortly before onset of diabetes and the incidence of ketonuria on admission to hospital at the onset of the disease. We also wanted to study the relation between HLA-antigens and the persistence of measurable C-peptide beyond the early remission period and to compare the HLA-antigens with the level of insulin antibodies.

Material

The study comprised 102 Caucasian non-related juvenile diabetics with age at onset of diabetes from 1–16 years (7.1 ± 3.9) and duration of diabetes of 1–17 years (6.6 ± 3.5). All of the patients had been treated with long acting insulin (Lente or NPH) once or twice daily, in many cases supplemented with intermediate or shortacting insulin (Semilente, Actrapid or Regular insulin). No patients had been given mono-component or rare immunogenic insulin at the time of the study.

C-Peptide and insulin antibodies (IgG and IRI) were determined in those 94 patients who had more than two years duration of diabetes and who were beyond the early remission period. Their age at onset

* This work was supported by the Swedish Medical Research Council no 16X-3557 and no 19X-04528, by the Swedish Diabetic Association and by the Medical Faculty, Linköping University, Sweden

Table 1. HLA phenotype frequencies (a) in patients with juvenile diabetes mellitus and in a non-diabetic Swedish population

HLA		102 patients		500 controls	
		n	a	RR	a
A	1	28	.275	1.31	.224
	2	71	.696	1.49	.606
	3	23	.226	0.62	.318
	9	24	.235	1.29	.192
	W25	5	.049	1.18	.042
	W26	4	.039	0.71	.055
	11	7	.069	0.69	.096
	28	8	.078	0.69	.110
	W19	12	.118	0.73	.154
	29	3	.029	0.98	.031
	W30	5	.049	3.72	.014
	W31	—	—	—	.048
	W32	2	.020	0.35	.055
B	5	7	.069	0.78	.086
	7	14	.137	0.40	.284 ^a
	8	39	.382	2.64	.190 ^b
	12	16	.157	0.49	.274
	13	5	.049	1.38	.036
	14	—	—	—	.024
	18	9	.088	1.33	.068
	27	9	.088	0.80	.108
	W15	32	.314	1.33	.256
	W16	6	.059	1.67	.036
	W17	3	.029	0.58	.050
	W21	4	.039	2.87	.014
	W22	6	.059	1.89	.032
	W35	2	.088	0.51	.160
C	W37	2	.020	0.45	.042
	W40	30	.294	1.59	.208
	W41	—	—	—	.006
	W1	3	.029	0.40	.070
	W2	7	.069	0.73	.092
	W3	45	.441	1.18	.400
	W4	12	.118	0.59	.185

^a = $p < 0.05$ ^b = $p < 0.01$

P corrected for 34 tested specificities

Table 2. Family history of diabetes, occurrence of infection within two months before onset of diabetes, ketonuria at onset of diabetes and age at onset of diabetes in relation to HLA-types

HLA	Family history of diabetes		Infection before onset		Ketonuria at onset		Age at onset	
	Total							
	n	n	%	n	%	n	%	mean $\pm$ SD
B8	39	10	25.6	12	30.8	33	84.6	6.5 3.7
BW15	32	12	37.5	9	28.1	27	84.4	6.5 3.8
B8, W15	11	4	36.4	5	45.5	9	81.8	5.2 ^b 2.8
B7	14	4	28.5	1	7.1 ^a	13	92.3	8.3 4.8
B18	9	1	11.1 ^b	3	33.3	8	88.9	7.1 2.8
All 102 patients		35	34.3	32	31.4	87	85.3	7.1 3.9

^a = $p < 0.05$ ^b = $p < 0.10$

of diabetes ranged from 1–16 years (6.9 ± 3.9) and duration of diabetes from 2–17 years (6.7 ± 3.3). The HLA-reference group consisted of 500 adult non-related non-diabetic individuals.

Methods

Clinical data were taken from the patient records supplemented by questionnaires regarding family history.

HLA-typing was performed by the lymphocytotoxic microtechnique described by Kissmeyer-Nielsen and Kjerbye [13]. Lymphocytes were isolated according to Thorsby [30] and Böyum [3]. The investigation included the following 34 HLA-antigens:

A: 1, 2, 3, 9, W25, W26, 11, 28, W19, 29, W30, W31, W32

B: 5, 7, 8, 12, 13, 14, 18, 27, W15, W16, W17, W21, W22, W35, W37, W40, W41

C: W1, W2, W3, W4

Blood for determination of C-peptide and insulin antibodies was drawn from the fasting patients prior to their morning insulin injection. Serum was stored at -18°C .

C-peptide was determined by a specific radioimmunoassay in which proinsulin is removed through binding to insulin antibodies covalently coupled to Sepharose [10]. Since most of the serum contained insulin antibodies, which have been shown to bind proinsulin, the serum was extracted at a low pH in the same way as described for total IRI [9] before the determination of C-peptide.

Insulin Antibodies: The binding of insulin to IgG was determined by a method according to Christiansen [5] and total immunoreactive insulin, IRI, was determined after acid extraction of serum according to Heding [9].

Statistical calculations of the relative risks (RR's) were performed with the methods described by Svejgaard et al. [28]. The χ^2 -test and Student's t-test were used to evaluate differences between subgroups of the material.

Results

The HLA-phenotype frequencies and relative risks are shown in Table 1. HLA-B8 was found in 39 of the 102 patients (38.2%). This means that the RR for juvenile diabetes among HLA-B8 positive individuals is 2.64 ($p < 0.01$). BW15 was found in 32 patients (31.4%) with RR 1.33 (n.s.). HLA-B8 and/or BW15 was found in 60 patients (58.8%) with RR 2.11 ($p < 0.05$). HLA-B8, W15 was found in 11 patients

Table 3. Fasting serum C-peptide in relation to HLA-types and duration of diabetes

HLA	Total	Duration of diabetes		C-peptide pmol/ml			p
				< 0.04		≥ 0.04	
		mean	± SD	n	%	n	
B8	36	7.0	3.8	25	69.4	11	< 0.10
BW15	28	7.3	3.5	22	78.6	6	
B8, W15	10	9.7	3.5	9	90.0	1	
B7	14	7.0	4.5	9	64.3	5	
B18	8	6.1	3.8	2	25.0	6	< 0.02
All patients	94	6.7	3.3	61		33	0.26 (0.04–2.30)

Table 4. Insulin binding capacity of IgG (insulin antibodies) in relation to HLA-types

HLA	IgG mU/ml					
	Total	< 0.300	0.300–2.000	> 2.000	mean	SD
B8	36	5	14	17	2.544	2.837
BW15	28	0 ^a	9	19 ^a	3.192	2.253
B8, W15	10	0	4	6	3.115	2.758
B7	14	3	9	2 ^b	1.571	1.499 ^a
B18	8	3	3	2	2.235	3.089
All patients	94	11	34	49	2.850	2.691

^a = $p < 0.05$ ^b = $p < 0.01$

(10.8%) with RR 2.76 ($p < 0.05$) HLA-B7 was found in 14 patients (13.7%) giving a significantly low RR of 0.40 ($p < 0.05$). The incidence of all other HLA-types did not differ significantly from that of the reference material.

In patients with the combination HLA-B8, W15, the age at onset of diabetes was 5.2 ± 2.8 years compared with 7.4 ± 4.0 years for the rest of the patients (Table 2, $p < 0.10$). A positive family history for juvenile and/or maturity onset diabetes (parents, siblings, grandparents) was found in 35 cases (34.3%). The frequency was the same in patients with HLA-B8 and/or BW15 as in the other groups, although it tended to be lower in patients with B18 ($p < 0.10$). A history of infection within two months before onset of diabetes was reported in 32 patients (31.4%). Patients with HLA-B8 and/or BW15 did not show more infections preceding onset than the other groups, but in patients with HLA-B7 infection before onset was significantly less common than in the other groups ($p < 0.05$). On first admission to hospital at the onset of diabetes 87 patients (85.3%) were ketonuric. Among these severe symptoms of keto-acidosis were seen in 14 patients, but nobody was unconscious. Ketouria occurred with the same frequency in all groups.

Table 5. Total serum insulin (IRI) in relation to some HLA-types

HLA	IRI μ U/ml					SD
	Total	< 300	300–1000	> 1000	mean	
B8	36	15 ^a	11	10	1356	2203
BW15	28	4 ^a	15	9	1551	2236
B8, W15	10	2	6	2	1490	2334
B7	14	6	5	3	580	640
B18	8	3	3	2	1236	1914
All patients	94	27	39	28	1221	1854

^a = $p < 0.05$

Measurable amounts of fasting C-peptide (≥ 0.04 pmol/ml) were found in 33 out of 94 patients (34.7%) with a mean value of 0.26 pmol/ml (range 0.04–2.30, Table 3). Measurable C-peptide seemed to be less common in patients with HLA-B8, W15 ($p < 0.10$) while patients with HLA-B18 had detectable C-peptide more often than the other groups ($p < 0.02$).

Insulin binding capacity of IgG is shown in Table 4. Antibodies (≥ 0.050 mU/ml) were found in all but 4 patients. Total serum insulin is shown in Table 5. In patients with HLA-BW15 high values of IgG were more common ($p < 0.05$) and low values of both IgG ($p < 0.05$) and IRI ($p < 0.05$) less frequent than in the other groups. Patients with HLA-B8 had the same mean value of IgG as the others but there were relatively more cases with low IRI values in this group ($p < 0.05$). Furthermore, patients with HLA-B7 had significantly lower values of IgG ($p < 0.05$) than the rest of the patients.

Discussion

Some alleles in the HLA-system are associated with certain diseases [22]. The HLA system is complex with at least four identified linked loci – 3 serologi-

Table 6. HLA-B8, HLA-BW15, and HLA-B7 in juvenile diabetes

Authors	HLA-B8			HLA-BW15			HLA-B7		
	n	RR	X ²	n	RR	X ²	n	RR	X ²
Present study	102	2.64	17.29	102	1.33	1.45	102	0.40	9.06
Finkelstein et al. [8]	28	1.67	1.26	28	2.89	2.84	28	0.85	0.12
Singal and Blajchman [27]	50	1.26	0.31	50	5.06	13.28	50	0.94	0.02
Cudworth and Woodrow [6]							50	0.40	4.98
Cudworth and Woodrow [7]	150	2.17	14.20	150	2.34	9.30			
Thomsen et al. [29]	85	2.60	18.11	85	2.25	11.59	85	0.32	10.23
Jansen et al. [11]	109	1.99	10.06	109	1.78	5.70	109	0.42	8.63
Cathelineau et al. [4]	55	4.19	14.00	55	0.91	0.04			
Schernthaner et al. [26]	50	3.30	14.67	50	3.33	11.16			
Ludwig et al. [15]							64	0.47	4.05
Total	629			629			488		
Combined RR		2.37			2.03			0.46	
X ²			82.45			42.40			31.18
p			< 0.0001			< 0.0001			< 0.0001

cally defined (HLA A, B, C) and one lymphocyte defined (HLA-D). Most of the investigations dealing with HLA and disease have so far mainly included the serologically defined antigens and the associations found have only involved alleles of the B locus. HLA-D locus is probably included among the immune response (Ir) genes [20]. The D locus is linked more closely to the B locus than to A and C loci, but increased B alleles are not always accompanied by an increase in D allele frequencies [21].

Table 6 compares the results of the present study with those of 9 previous studies with regard to the combined risks for HLA-B8, BW15 and B7 in juvenile diabetes [4, 6, 7, 8, 11, 15, 26, 27, 29]. All authors have found an increased frequency of HLA-B8 and the combined RR is significantly increased ($p < 0.0001$). There was a non-significant increase of BW15 in our study. However, this allele was more common in our reference group than in other reference groups. In all but one of the other studies mentioned in Table 6 an increased frequency of BW15 has been reported and the combined RR is significantly increased ($p < 0.0001$). In all studies the RR for HLA-B7 positive individuals is less than unity and the combined RR is significantly low ($p < 0.0001$). Perhaps HLA-B7 is associated with a gene protective against juvenile diabetes [15].

In one of the 9 previous studies mentioned above D-typing was reported. RR for DW3 was found to be higher than RR for B8 [29].

In individuals with HLA-B8 certain virus infections have been suggested as provoking an immune response leading to destruction of the B-cells and an insulin dependent type of diabetes [14, 24]. However, epidemiological studies have given divergent results [1, 25]. In the present diabetic population there was no correlation between HLA-B8 and/or BW15 and the occurrence of infection within two months before

onset of diabetes. On the other hand infections seemed to be less common before onset of diabetes in patients with HLA-B7.

As C-peptide and insulin are secreted from the B-cells in equimolar amounts, C-peptide has been used as a measure of the endogenous insulin production in insulin treated diabetics [2]. It has been generally accepted that in most cases of juvenile diabetes the production of insulin by the B-cells is either drastically reduced or totally eliminated shortly after the onset of the disease [19]. However, some juvenile diabetics have measurable amounts of C-peptide not only during but also after the early remission period [16], indicating some residual B-cell function. If HLA-B8 or other HLA-antigens were related to an immune response leading to destruction of B-cells and a more severe form of insulin dependent diabetes, one would expect minimal levels of serum C-peptide in patients with such HLA-antigens.

In this study patients with HLA-B8 and/or BW15 did not differ significantly from other patients with regard to the C-peptide levels, but the results suggest that if both alleles of the B locus are occupied by diabetes predisposing genes, the RR of getting diabetes is higher, onset of diabetes seems to be earlier and B-cell damage more severe. The significantly increased incidence of measurable C-peptide in the small group of patients with HLA-B18 (which occurred in normal frequency) may imply that this HLA antigen is combined with a milder form of diabetes. However, an alternative explanation is the somewhat shorter duration of diabetes among these patients (Table 3).

The high levels of insulin antibodies found in this study may be due to treatment with immunogenic insulins. However, the degree of antibody production may also be genetically determined and associated with certain histocompatibility genes [12]. The results

of the present study (Table 4–5) support the hypothesis that a genetic mechanism may be involved. — As it has been demonstrated that high levels of insulin antibodies are negatively correlated to the level of C-peptide in juvenile diabetics beyond the early remission period [16], and also negatively correlated to the degree of metabolic control [17], it may be relevant to suppose that not only absence of endogenous insulin production but also high levels of insulin antibodies mean a more severe form as juvenile diabetes.

HLA-B8 positive patients do not seem to be predisposed to a more severe form of diabetes as far as can be seen from the determination of C-peptide levels and the levels of insulin antibodies. HLA-BW15 positive patients, however, might be predisposed to produce more insulin antibodies than others [11]. Individuals with HLA-B7 seem to have a diminished risk of getting juvenile diabetes, and in this study diabetics with HLA-B7 had lower levels of insulin antibodies. These results suggest that HLA-B7 and possibly HLA-B18 might be associated with a different and perhaps milder form of juvenile diabetes.

Acknowledgements. We wish to thank Mrs Gun Bjare, Mrs Eva Cornell, Miss Bente Hansen, Miss Marianne Knudsen and Miss Viola Selling for their excellent technical assistance.

References

- Barbosa, J., Noreen, H., Goetz, F., Simmons, R., Najarian, J., Yunies, E.J.: Juvenile diabetes and viruses. *Lancet* **1976***I*, 371
- Block, M.B., Mako, M.E., Steiner, D.F., Rubenstein, A.H.: Circulating C-peptide immunoreactivity. Studies in normals and diabetic patients. *Diabetes* **21**, 1013–1026 (1972)
- Bøyum, A.: Separation of leukocytes from blood and bone marrow. *Scand. J. clin. Lab. Invest.* **21**, (Suppl.) 97 (1968)
- Cathelineau, G., Cathelineau, L., Hora, J., Schmid, M., Dausset, J.: HL-A and juvenile diabetes. Eleventh Annual Meeting of the European Association for the Study of Diabetes. *Diabetologia* **11**, (Abstr.) 355 (1975)
- Christiansen, Aa.H.: Radioimmuno-electrophoresis in the determination of insulin binding to IgG. Methodological studies. *Horm. Metab. Res.* **5**, 147–154 (1973)
- Cudworth, A.G., Woodrow, J.C.: HL-A system and diabetes mellitus. *Diabetes* **24**, 345–349 (1975)
- Cudworth, A.G., Woodrow, J.C.: Evidence for HL-A linked genes in “juvenile” diabetes mellitus. *Brit. med. J.* **1975** **III**, 133–135
- Finkelstein, S., Zeller, E., Walford, R.L.: No relation between HL-A and juvenile diabetes. *Tissue Antigens* **2**, 74–77 (1972)
- Heding, L.G.: Determination of total serum insulin (IRI) in insulin-treated diabetic patients. *Diabetologia* **8**, 260–266 (1972)
- Heding, L.G.: Radioimmunological determination of human C-peptide in serum. *Diabetologia* **11**, 541–548 (1975)
- Jansen, F.K., Bertrams, J., Jansen, F.K., Grünekle, D., Drost, H., Reis, H.E., Bever, J., Kuwert, E., Gries, F.A., Altröck, E.: Genetic association of the insulin-antibody production with histocompatibility (HL-A)-antigens in diabetics. Eleventh Annual Meeting of the European Association for the Study of Diabetes. *Diabetologia* **11**, (Abstr.) 352–353 (1975)
- Kiesel, U., Jansen, F.K.: Influence of histocompatibility antigens and of “foreignness” of insulin on titre and heterogeneity of insulin antibodies. Eleventh Annual Meeting of the European Association for the Study of Diabetes. *Diabetologia* **11**, (Abstr.) 355 (1975)
- Kissmeyer-Nielsen, F., Kjerbye, K.E.: Lymphocytotoxic microtechnique. Purification of lymphocytes by flotation. In: *Histocompatibility testing*, pp. 381–383. Copenhagen: Munksgaard 1967
- Leading article: Autoimmune diabetes mellitus. *Lancet* **1974** **II**, 1549–1551
- Ludwig, H., Scherthaner, G., Mayr, W.R.: Is HLA-B7 a marker associated with a protective gene in juvenile-onset diabetes mellitus? *New. Engl. J. Med.* **294**, 1066 (1976)
- Ludvigsson, J., Heding, L.G.: C-peptide in children with juvenile diabetes. A preliminary report. *Diabetologia* **12**, 627–630 (1976)
- Ludvigsson, J., Heding, L.G., Larsson, Y., Leander, E.: C-peptide in juvenile diabetics beyond the postinitial remission period. — Relation to clinical manifestations at onset of diabetes, remission and diabetic control. *Acta paediat. scand.* (To be published)
- Löw, B., Scherstén, B., Sartor, G., Thulin, T., Mittelman, F.: HL-A8 and W15 in diabetes mellitus and essential hypertension. *Lancet* **1975** **I**, 695
- Marble, A., White, P., Bradley, R.F., Krall, L.P., (eds): *Joslin's diabetes mellitus*. 11 ed. Philadelphia: Lea and Febiger 1971
- McDevitt, H.O., Bodmer, W.F.: HL-A, immune-response genes and disease. *Lancet* **1974** **I**, 1269–1275
- Möller, E., Hammarström, L., Smith, E., Matell, G.: HL-A8 and LD-8a in patients with myasthenia gravis. *Tissue Antigens* **7**, 39–44 (1976)
- Möller, G., (ed): *Transplant. Rev.* **22**, 1975
- Nerup, J., Ortvad Andersen, O., Christy, M., Platz, P., Thomsen, M., Svejgaard, A., Botazzo, F., Pouplard, A., Doniach, D.: HL-A factors, autoimmunity, virus and juvenile diabetes mellitus. Eleventh Annual Meeting of the European Association for the Study of Diabetes. *Diabetologia* **11**, (Abstr.) 365–366 (1975)
- Nerup, J., Platz, P., Ortvad Andersen, O., Christy, M., Lyngsøe, J., Poulsen, J.E., Ryder, L.P., Thomsen, M., Staub Nielsen, L., Svejgaard, A.: HL-A antigens and diabetes mellitus. *Lancet* **1974** **II**, 864–866
- Rolles, C.J., Rayner, P.H.W., Mackintosh, P.: Aetiology of juvenile diabetes. *Lancet* **1975** **II**, 230
- Scherthaner, G., Mayr, W.R., Pacher, M., Ludwig, H., Erd, W., Eibl, M.: HL-A8, W15 and T3 in juvenile-onset diabetes mellitus. *Horm. Metab. Res.* **7**, 521–522 (1975)
- Singal, D.P., Blajchman, M.D.: Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. *Diabetes* **22**, 429–432 (1973)
- Svejgaard, A., Jersild, C., Staub-Nielsen, L., Bodmer, W.F.: HL-A antigens and disease. Statistical and genetical considerations. *Tissue Antigens* **4**, 95–105 (1974)
- Thomsen, M., Platz, P., Ortvad Andersen, O., Christy, M., Lyngsøe, J., Nerup, J., Rasmussen, K., Ryder, L.P., Staub Nielsen, L., Svejgaard, A.: MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. *Transplant. Rev.* **22**, 125–147 (1975)
- Thorsby, E.: Cell specific and common antigens on human granulocytes and lymphocytes demonstrated with cytotoxic heteroantibodies. *Vox Sang. (Basel)* **13**, 194–206 (1967)

Received: June 8, 1976, and in revised form: September 28, 1976

Dr. J. Ludvigsson
Linköping Univ.
Dept. of Pediatrics
S-581 85 Linköping
Sweden